3MATTI S.Cell-mediated immune responses and loss of hepatitis B e-antigen(HBeAg)during successful lamivudine and famciclovir combination therapy for chronic replicating hepatitis B virus infection[J].Clin Infec Dise,1999,29:1575-1577.
4HUNT C,MCGILL J,ALLEN M,et al.Clinical relevance of hepatitis B viral mutations[J].Hepatology,2000,31(5):1037-1044.
5CHAN H,LEUNG N,WONG M,et al.Patitis B e antigen-negative chronic hepatitis B in Hong Kong[J].Hepatology,2000,31(3):763-768.
6MARUSAWA H,UEMOTO S,HIJKATA M,et al.Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen[J].Hepatology,2000,31(2):488-495.
7RAHMAN F,DAHMEN A,SABINE H,et al.Cellular and humoral immune respones induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen[J].Hepatology,2000,31(2):521-527.
8Doong S L,Tsai C H,Schinazi R F,et al.Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues[J].Proc Natl Acad Sci USA,1991,88:8495-8499.
9De Clercq E.Perspectives for the treatment of hepatitis B virus infections[J].Int J Antimicrob Agents,1999,12(2):81-95.
10Yang J,Bo X C,Ding X R,et al.Antisense oligonucleotides targeted against asialoglycoprotein receptor(ASGPR)block human hepatitis B virus replication[J].J Viral Hepatitis.(in press).
